JP2020502106A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502106A5 JP2020502106A5 JP2019531623A JP2019531623A JP2020502106A5 JP 2020502106 A5 JP2020502106 A5 JP 2020502106A5 JP 2019531623 A JP2019531623 A JP 2019531623A JP 2019531623 A JP2019531623 A JP 2019531623A JP 2020502106 A5 JP2020502106 A5 JP 2020502106A5
- Authority
- JP
- Japan
- Prior art keywords
- bipolar disorder
- pharmaceutical composition
- formula
- group
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160170224 | 2016-12-14 | ||
| KR10-2016-0170224 | 2016-12-14 | ||
| PCT/KR2017/014740 WO2018111008A1 (ko) | 2016-12-14 | 2017-12-14 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502106A JP2020502106A (ja) | 2020-01-23 |
| JP2020502106A5 true JP2020502106A5 (enExample) | 2021-01-14 |
| JP7208139B2 JP7208139B2 (ja) | 2023-01-18 |
Family
ID=62559442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531623A Active JP7208139B2 (ja) | 2016-12-14 | 2017-12-14 | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11571410B2 (enExample) |
| EP (1) | EP3556366B1 (enExample) |
| JP (1) | JP7208139B2 (enExample) |
| KR (1) | KR102635938B1 (enExample) |
| CN (1) | CN110290788A (enExample) |
| AU (1) | AU2017374458B2 (enExample) |
| BR (1) | BR112019011930A2 (enExample) |
| CL (1) | CL2019001618A1 (enExample) |
| ES (1) | ES3054693T3 (enExample) |
| IL (1) | IL267195B2 (enExample) |
| MX (1) | MX2019006940A (enExample) |
| MY (1) | MY199104A (enExample) |
| WO (1) | WO2018111008A1 (enExample) |
| ZA (1) | ZA201903747B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021003203A (es) * | 2018-09-21 | 2021-05-27 | Sk Biopharmaceuticals Co Ltd | Compuesto de carbamato y uso de la formulacion que comprende el mismo en prevenir, aliviar, o tratar trastorno de estres agudo o trastorno de estres post-traumatico. |
| EP3854392A4 (en) * | 2018-09-21 | 2022-08-17 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES |
| KR20220104746A (ko) * | 2019-11-22 | 2022-07-26 | 에스케이바이오팜 주식회사 | 카바메이트 화합물을 포함하는 경구용 약제학적 조성물 및 그 제조방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2297732C (en) * | 1997-08-14 | 2008-04-29 | F. Hoffmann-La Roche Ag | Heterocyclic vinylethers against neurological disorders |
| KR100843703B1 (ko) | 2000-07-21 | 2008-07-04 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 | 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도 |
| CZ20032300A3 (cs) * | 2001-02-27 | 2005-01-12 | Ortho-Mcneil Pharmaceutical, Inc. | Léčivo pro prevenci nebo léčbu bipolárních chorob |
| HUP0303261A3 (en) * | 2001-02-27 | 2012-07-30 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing or treating bipolar disorder |
| AU2005307797B2 (en) * | 2004-11-16 | 2011-06-02 | Alkermes Pharma Ireland Limited | Injectable nanoparticulate olanzapine formulations |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| CA2667909A1 (en) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | Treatment of pervasive developmental disorders |
| BRPI0924997B1 (pt) | 2009-06-22 | 2024-01-16 | Sk Biopharmaceuticals Co., Ltd | Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US9981950B2 (en) * | 2014-08-15 | 2018-05-29 | Janssen Pharmaceuticals, Inc. | Triazoles as NR2B receptor inhibitors |
-
2017
- 2017-12-14 JP JP2019531623A patent/JP7208139B2/ja active Active
- 2017-12-14 AU AU2017374458A patent/AU2017374458B2/en active Active
- 2017-12-14 BR BR112019011930-2A patent/BR112019011930A2/pt not_active Application Discontinuation
- 2017-12-14 MY MYPI2019003348A patent/MY199104A/en unknown
- 2017-12-14 EP EP17881161.8A patent/EP3556366B1/en active Active
- 2017-12-14 CN CN201780077574.0A patent/CN110290788A/zh active Pending
- 2017-12-14 US US16/468,782 patent/US11571410B2/en active Active
- 2017-12-14 WO PCT/KR2017/014740 patent/WO2018111008A1/ko not_active Ceased
- 2017-12-14 IL IL267195A patent/IL267195B2/en unknown
- 2017-12-14 KR KR1020197018408A patent/KR102635938B1/ko active Active
- 2017-12-14 MX MX2019006940A patent/MX2019006940A/es unknown
- 2017-12-14 ES ES17881161T patent/ES3054693T3/es active Active
-
2019
- 2019-06-11 ZA ZA2019/03747A patent/ZA201903747B/en unknown
- 2019-06-12 CL CL2019001618A patent/CL2019001618A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512531A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2024543976A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| RU2015143610A (ru) | Лечение катаплексии | |
| JP2017527532A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| JP2009541223A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2014511891A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2016503797A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| RU2018113718A (ru) | Новые соединения | |
| JP2019529444A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2011509302A5 (enExample) | ||
| JP2021504384A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| RU2011147186A (ru) | 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3 | |
| JP2011518168A5 (enExample) |